Clinical trials: Vulva Cancer

Human Papilloma Virus, Cervical Cancer

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

• Completed
• Age: 18 to 24 years
• Phase 1
• Vaccines
• Results posted

This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIX™ (IMX).

Conditions

Human Papilloma Virus, Cervical Cancer, Vulvar Cancer, Vaginal Cancer

Trial name

NCT00851643

Testing

Octavalent HPV with 15 mcg IMX / AAHS, Octavalent HPV with 30 mcg IMX / AAHS, Octavalent HPV with 60 mcg IMX / AAHS

Volunteers

158 people, healthy volunteers welcome

Sponsor

Merck Sharp & Dohme LLC